This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Amantana, A. Articles by Devi, G. R. Search for Related Content PubMed PubMed Citation Articles by Amantana, A. Articles by Devi, G. R.

AVI BioPharma, Inc. Corvallis, Oregon

Requests for reprints: Gayathri R. Devi, Cancer and Endocrine Program, AVI BioPharma, Inc., 4575 SW Research Way, Suite 200, Corvallis, OR 97333. Phone: 541-753-3635; Fax: 541-754-3545. E-mail: grdevi{at}avibio.com

Androgen-insensitive prostate cancer cells are highly resistant to several chemotherapeutic drugs and are characterized by the appearance of apoptosis-resistant cells. In this study, we identified the critical role of X-linked inhibitor of apoptosis protein (XIAP), a potent antiapoptotic factor, in conferring chemotherapy resistance in an androgen-insensitive DU145 human prostate cancer cell line. Results reveal that DU145 cells were highly resistant to cisplatin, but this resistance was overridden when the cells were treated for a prolonged time (>96 hours) with cisplatin (IC₅₀ = 27.5 to 35.5 µmol/L). A decrease in levels of XIAP and Akt/phospho-Akt and an increase in caspase-3 activity were identified to be key factors in cisplatin sensitivity (40% to 55% decrease in cell viability) at later time points. In contrast, tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) treatment caused a 40% to 50% decrease in cell viability within 6 hours (IC₅₀ = 135 to 145 ng/mL). However, increasing concentrations or prolonged treatment with TRAIL did not change drug potency. A significant increase in caspase-3 activity was observed with TRAIL treatment with no apparent change in XIAP levels. Specific inhibition of XIAP expression using an antisense XIAP phosphorodiamidate morpholino oligomer induced apoptosis and increased caspase-3 activity. Combination of cisplatin with XIAP antisense potentiated cisplatin sensitivity by decreasing the IC₅₀ from >200 µmol/L with cisplatin alone to 9 to 20 µmol/L and decreasing incubation time required for activity from 96 to 24 hours. Similarly, TRAIL in combination with XIAP antisense phosphorodiamidate morpholino oligomer enhanced TRAIL potency by 12- to 13-fold. In conclusion, abrogation of XIAP expression is essential for therapeutic apoptosis and enhanced chemotherapy sensitization in androgen-refractory prostate cancer cells.

Received 9/16/03; revised 3/22/04; accepted 4/ 6/04.

This article has been cited by other articles:

				C. Wilson, T. Wilson, P. G. Johnston, D. B. Longley, and D. J.J. Waugh Interleukin-8 signaling attenuates TRAIL- and chemotherapy-induced apoptosis through transcriptional regulation of c-FLIP in prostate cancer cells Mol. Cancer Ther., September 1, 2008; 7(9): 2649 - 2661. [Abstract] [Full Text] [PDF]

				S. Shankar, Q. Chen, S. Ganapathy, K. P. Singh, and R. K. Srivastava Diallyl trisulfide increases the effectiveness of TRAIL and inhibits prostate cancer growth in an orthotopic model: molecular mechanisms Mol. Cancer Ther., August 1, 2008; 7(8): 2328 - 2338. [Abstract] [Full Text] [PDF]

				M. Ying, C. Tu, H. Ying, Y. Hu, Q. He, and B. Yang MSFTZ, a Flavanone Derivative, Induces Human Hepatoma Cell Apoptosis via a Reactive Oxygen Species- and Caspase-Dependent Mitochondrial Pathway J. Pharmacol. Exp. Ther., June 1, 2008; 325(3): 758 - 765. [Abstract] [Full Text] [PDF]

				K. M. Aird, X. Ding, A. Baras, J. Wei, M. A. Morse, T. Clay, H. K. Lyerly, and G. R. Devi Trastuzumab signaling in ErbB2-overexpressing inflammatory breast cancer correlates with X-linked inhibitor of apoptosis protein expression Mol. Cancer Ther., January 1, 2008; 7(1): 38 - 47. [Abstract] [Full Text] [PDF]

				S. P. Zehntner, L. Bourbonniere, C. S. Moore, S. J. Morris, D. Methot, M. St. Jean, E. Lacasse, A. L. O. Hebb, G. S. Robertson, J. Durkin, et al. X-linked Inhibitor of Apoptosis Regulates T Cell Effector Function J. Immunol., December 1, 2007; 179(11): 7553 - 7560. [Abstract] [Full Text] [PDF]

				C. A. Karikari, I. Roy, E. Tryggestad, G. Feldmann, C. Pinilla, K. Welsh, J. C. Reed, E. P. Armour, J. Wong, J. Herman, et al. Targeting the apoptotic machinery in pancreatic cancers using small-molecule antagonists of the X-linked inhibitor of apoptosis protein Mol. Cancer Ther., March 1, 2007; 6(3): 957 - 966. [Abstract] [Full Text] [PDF]

				H. Sasaki, N. Ohara, Q. Xu, J. Wang, D. A. DeManno, K. Chwalisz, S. Yoshida, and T. Maruo A Novel Selective Progesterone Receptor Modulator Asoprisnil Activates Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)-Mediated Signaling Pathway in Cultured Human Uterine Leiomyoma Cells in the Absence of Comparable Effects on Myometrial Cells J. Clin. Endocrinol. Metab., February 1, 2007; 92(2): 616 - 623. [Abstract] [Full Text] [PDF]

				H. H. Cheung, E. C. LaCasse, and R. G. Korneluk X-linked inhibitor of apoptosis antagonism: strategies in cancer treatment. Clin. Cancer Res., June 1, 2006; 12(11): 3238 - 3242. [Full Text] [PDF]

				L. A. Gomez, A. de las Pozas, and C. Perez-Stable Sequential combination of flavopiridol and docetaxel reduces the levels of X-linked inhibitor of apoptosis and AKT proteins and stimulates apoptosis in human LNCaP prostate cancer cells Mol. Cancer Ther., May 1, 2006; 5(5): 1216 - 1226. [Abstract] [Full Text] [PDF]

				S. Mohapatra, B. Chu, X. Zhao, and W.J. Pledger Accumulation of p53 and Reductions in XIAP Abundance Promote the Apoptosis of Prostate Cancer Cells Cancer Res., September 1, 2005; 65(17): 7717 - 7723. [Abstract] [Full Text] [PDF]

				G. R. Devi, T. M. Beer, C. L. Corless, V. Arora, D. L. Weller, and P. L. Iversen In vivo Bioavailability and Pharmacokinetics of a c-MYC Antisense Phosphorodiamidate Morpholino Oligomer, AVI-4126, in Solid Tumors Clin. Cancer Res., May 15, 2005; 11(10): 3930 - 3938. [Abstract] [Full Text] [PDF]